MedCity News
ASCO 2021 recap: Lynparza’s lift, Grail goes on, LAG validation & more
The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.
Shares0
The annual meeting of the America Society of Clinical Oncology came and went, and for the second year in a row, the pandemic meant that the cancer gathering was an all-digital affair.
Big pharmaceutical companies grabbed most of the headlines with data supporting further development of some clinical candidates and in at least one case, potential expanded use of a blockbuster cancer drug as an earlier treatment. Targeted therapies have been gaining steam and this year’s conference saw the unveiling of data validating some new targets. Here’s a look back at some of the highlights
Senda Biosciences is developing drugs based on an understanding of intersystems biology the way that humans interact with bacteria and plants. The startup, founded by Flagship Pioneering, has added $55 million to advance its three lead programs to clinical testing next year.
Glen Tullman’s newest healthcare navigation startup, Transcarent, raised another $58 million in funding. The company plans to use the funds to quickly build out its offering for employers.
On the final day of INVEST Precision Medicine, a panel with Caris Health, CVS Health, and Intermountain Healthcare will share assessments of precision medicine's progress and the outlook for this sector. Also, a panel will highlight non dilutive funding opportunities for startups. Register now!